Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.39 |
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981266 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL984566 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL983617 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL335169 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL262090 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL653851 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL17416222 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL134759 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL63139 | 1.00 | — | — | |
| SCHEMBL982460 | 1.00 | THRB (0.44) | THRBTSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | claimed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | claimed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | claimed |
| CN-118302407-A | Carbonyl compound, method for producing isocyanate compound, and isocyanate composition | 旭化成株式会社 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023080257-A1 | METHOD FOR PRODUCING ISOCYANATE COMPOUNDS, METHOD FOR PRODUCING CARBAMATE COMPOUNDS, METHOD FOR RECOVERING AMINE COMPOUNDS, AND ISOCYANATE COMPOSITION | 旭化成株式会社 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023080258-A1 | CARBONYL COMPOUND, METHOD FOR PRODUCING CARBONYL COMPOUND, METHOD FOR PRODUCING ISOCYANATE COMPOUND, AND ISOCYANATE COMPOSITION | 旭化成株式会社 | 2023-05-11 | — | — | WO | disclosed |
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| EP-2966702-A1 | ORGANIC SEMICONDUCTOR THIN FILM PRODUCTION METHOD | National University Corporation Kobe University (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| EP-2088138-B1 | Process for producing isocyanate | ASAHI KASEI CHEMICALS CORP (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-8362293-B2 | Process for producing isocyanates | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2275406-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20100069665-A1 | PROCESS FOR PRODUCING ISOCYANATES | AHAHI KASEI CHEMICALS CORPORATION (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2088138-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2009-08-12 | — | — | EP | disclosed |
| US-5986042-A | Cross-linked polymer | MITSUI CHEMICALS, INC. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0856539-A1 | Cross-linked polymer | Mitsui Chemicals, Inc. (JP) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | CPS1, PHGDH, APEH | THRB 4857/4885TSHR 4853/4885MEN1 2713/4885 |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | THRB 1729/4885TSHR 3606/4885MEN1 4546/4885 |
| US-20100069665-A1 | PROCESS FOR PRODUCING ISOCYANATES | CPS1, IDH2, PHGDH | THRB 4860/4885TSHR 4775/4885MEN1 1653/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | THRB 1729/4885TSHR 3606/4885MEN1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.